Maturation of the Human Immunoglobulin Heavy Chain Repertoire With Age

Autor: Ghraichy, M, Galson, JD, Kovaltsuk, A, von Niederhäusern, V, Pachlopnik Schmid, J, Recher, M, Jauch, AJ, Miho, E, Kelly, DF, Deane, CM, Trück, J

Publikováno v: Frontiers in Immunology

B cells play a central role in adaptive immune processes, mainly through the production of antibodies. The maturation of the B cell system with age is poorly studied. We extensively investigated age-related alterations of naïve and antigen-experienc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e3b8567288b7613e85f46a5f6d4b9668
https://www.zora.uzh.ch/id/eprint/193090/

Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures

Autor: Jacob D. Galson, Sebastian Schaetzle, Rachael J. M. Bashford-Rogers, Matthew I. J. Raybould, Aleksandr Kovaltsuk, Gavin J. Kilpatrick, Ralph Minter, Donna K. Finch, Jorge Dias, Louisa K. James, Gavin Thomas, Wing-Yiu Jason Lee, Jason Betley, Olivia Cavlan, Alex Leech, Charlotte M. Deane, Joan Seoane, Carlos Caldas, Daniel J. Pennington, Paul Pfeffer, Jane Osbourn

Publikováno v: Frontiers in Immunology
Scientia
Frontiers in Immunology, Vol 11 (2020)

Repertori de cèl·lules B; SARS-CoV-2; Anticòs Repertorio de células B; SARS-CoV-2; Anticuerpo B-cell repertoire; SARS-CoV-2; Antibody Deep sequencing of B cell receptor (BCR) heavy chains from a cohort of 31 COVID-19 patients from the UK reveals

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fbba260540fc77b9f995e77a5aec3ea
https://www.repository.cam.ac.uk/handle/1810/317256

Predictability of B cell clonal persistence and immunosurveillance in breast cancer.

Autor: Sammut SJ; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. stephen-john.sammut@icr.ac.uk.; The Royal Marsden Hospital NHS Foundation Trust, London, UK. stephen-john.sammut@icr.ac.uk., Galson JD; Alchemab Therapeutics, Whittlesford, UK., Minter R; Alchemab Therapeutics, Whittlesford, UK., Sun B; Wellcome Centre for Human Genetics, Oxford, UK.; Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK., Chin SF; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., De Mattos-Arruda L; IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain.; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain., Finch DK; Alchemab Therapeutics, Whittlesford, UK., Schätzle S; Alchemab Therapeutics, Whittlesford, UK., Dias J; Alchemab Therapeutics, Whittlesford, UK., Rueda OM; MRC Biostatistics Unit, University of Cambridge, Cambridge, UK., Seoane J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Institució Catalana de Recerca i Estudis Avançats (ICREA), Universitat Autònoma de Barcelona (UAB), CIBERONC, Barcelona, Spain., Osbourn J; Alchemab Therapeutics, Whittlesford, UK., Caldas C; School of Clinical Medicine, University of Cambridge, Cambridge, UK. cc234@cam.ac.uk., Bashford-Rogers RJM; Wellcome Centre for Human Genetics, Oxford, UK. rachael.bashford-rogers@bioch.ox.ac.uk.; Department of Biochemistry, University of Oxford, Oxford, UK. rachael.bashford-rogers@bioch.ox.ac.uk.; Oxford Cancer Centre, Oxford, UK. rachael.bashford-rogers@bioch.ox.ac.uk.

Publikováno v: Nature immunology [Nat Immunol] 2024 May; Vol. 25 (5), pp. 916-924. Date of Electronic Publication: 2024 May 02.

Becoming fluent in proteins.

Autor: Leem J; Alchemab Therapeutics Ltd, East Side, Office 1.02, King's Cross, London N1C 4AX, UK. Electronic address: jin@alchemab.com., Galson JD; Alchemab Therapeutics Ltd, East Side, Office 1.02, King's Cross, London N1C 4AX, UK. Electronic address: jake@alchemab.com.

Publikováno v: Cell systems [Cell Syst] 2023 Nov 15; Vol. 14 (11), pp. 923-924.

Characterisation of the immune repertoire of a humanised transgenic mouse through immunophenotyping and high-throughput sequencing.

Autor: Richardson E; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, United Kingdom.; Department of Statistics, University of Oxford, Oxford, United Kingdom., Binter Š; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, United Kingdom., Kosmac M; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, United Kingdom., Ghraichy M; Division of Immunology, University Children's Hospital, University of Zurich, Zurich, Switzerland.; Children's Research Center, University of Zurich, Zurich, Switzerland., von Niederhäusern V; Division of Immunology, University Children's Hospital, University of Zurich, Zurich, Switzerland.; Children's Research Center, University of Zurich, Zurich, Switzerland., Kovaltsuk A; Department of Statistics, University of Oxford, Oxford, United Kingdom., Galson JD; Alchemab Therapeutics Ltd, Kings Cross, London, United Kingdom., Trück J; Division of Immunology, University Children's Hospital, University of Zurich, Zurich, Switzerland.; Children's Research Center, University of Zurich, Zurich, Switzerland., Kelly DF; Department of Paediatrics, University of Oxford, Oxford, United Kingdom., Deane CM; Department of Statistics, University of Oxford, Oxford, United Kingdom., Kellam P; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, United Kingdom.; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom., Watson SJ; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, United Kingdom.

Publikováno v: ELife [Elife] 2023 Mar 27; Vol. 12. Date of Electronic Publication: 2023 Mar 27.